AstraZeneca (AZN LN) Q3 2026 (USD): Revenue 16.2bln (exp. 16bln), Adj. EPS 2.79 (exp. 2.59). Confirms FY26 guidance
ORIGINAL · NewsquawkAstraZeneca (AZN LN) Q3 2026 (USD): Revenue 16.2bln (exp. 16bln), Adj. EPS 2.79 (exp. 2.59). Confirms FY26 guidanceRead originalHide original
Announces cost-savings plan over three years, including a USD 2bln one-time restructuring charge and to deliver USD 1.5bln in annual pretax savings, which will be reinvested mainly into the pipeline of new drugs. CEO: "We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars." "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.”
AstraZeneca reported Q3 revenue and adjusted EPS above expectations, confirmed FY26 guidance without figures, and outlined cost savings and pipeline updates.
News detail
Announces cost-savings plan over three years, including a USD 2bln one-time restructuring charge and to deliver USD 1.5bln in annual pretax savings, which will be reinvested mainly into the pipeline of new drugs. CEO: "We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars." "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.”
Related stocks
1 stocks
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.